Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DeepTrace Technologies has developed and deployed artificial intelligence platforms that analyze biometric data and medical images such as MRI, CT scans, and ultrasound to provide early diagnosis and prognosis of neurodegenerative diseases like Alzheimer's disease as well as ovarian cancer. Their TRACE4AD tool predicts the likelihood of progression from mild cognitive impairment to Alzheimer’s dementia within 24 months. TRACE4OC assesses the risk of ovarian cancer based on ultrasound imaging. These tools are designed to support clinicians in early detection, differential diagnosis, treatment targeting, and prognosis.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on DeepTrace Technologies.